Four-Pronged attack on tough stomach cancers enters next testing phase
NCT ID NCT06109467
Summary
This study is testing a new combination of four drugs for people with advanced stomach or esophageal cancer that has a specific genetic feature called HER2. The goal is to see if adding the drug neratinib to standard chemotherapy and two other targeted drugs is safe and more effective at shrinking tumors. Researchers will enroll about 36 patients to measure how well the tumors respond and how long the treatment keeps the cancer under control.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Moffitt Cancer Center
RECRUITINGTampa, Florida, 33612, United States
Contact
Conditions
Explore the condition pages connected to this study.